Tesaro licenses cancer technology from Amgen

03/23/2011 | Mass High Tech (Boston)

Amgen agreed to exclusively license its anaplastic lymphoma kinase technology to Tesaro to help develop drugs for nonsmall-cell lung cancer. The deal calls for Tesaro to pay upfront and milestone fees to Amgen in exchange for development, production and marketing rights to ALK small-molecule drugs.

View Full Article in:

Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC